Press coverage about Henry Schein (NASDAQ:HSIC) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Henry Schein earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.5431828712918 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
A number of research analysts have recently commented on the company. Zacks Investment Research lowered Henry Schein from a “buy” rating to a “hold” rating in a report on Thursday, May 10th. ValuEngine lowered Henry Schein from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 2nd. Northcoast Research set a $102.00 price objective on Henry Schein and gave the company a “buy” rating in a report on Tuesday, April 24th. Barclays reissued a “hold” rating and set a $73.00 price objective on shares of Henry Schein in a report on Wednesday, May 9th. Finally, BidaskClub raised Henry Schein from a “sell” rating to a “hold” rating in a report on Saturday, April 14th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. Henry Schein has a consensus rating of “Hold” and an average target price of $81.59.
HSIC opened at $74.86 on Wednesday. The company has a market capitalization of $11.50 billion, a price-to-earnings ratio of 20.79, a price-to-earnings-growth ratio of 1.78 and a beta of 1.00. The company has a current ratio of 1.44, a quick ratio of 0.74 and a debt-to-equity ratio of 0.34. Henry Schein has a 12-month low of $62.56 and a 12-month high of $93.14.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, May 8th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.03. The firm had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.18 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 EPS. research analysts expect that Henry Schein will post 4.1 EPS for the current fiscal year.
In other Henry Schein news, Director Paul Brons sold 4,822 shares of the firm’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $72.93, for a total value of $351,668.46. Following the completion of the sale, the director now owns 20,889 shares in the company, valued at approximately $1,523,434.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark E. Mlotek sold 10,359 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $72.73, for a total value of $753,410.07. Following the completion of the sale, the executive vice president now owns 79,506 shares of the company’s stock, valued at approximately $5,782,471.38. The disclosure for this sale can be found here. Company insiders own 1.15% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.